Indian pharmaceutical stocks declined sharply after former US President Donald Trump threatened to impose tariffs on pharma imports, unsettling investor sentiment. Despite India’s dominant role in the US generics market, the proposed tariffs could raise medication costs for American consumers and disrupt global supply chains.